Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for T

ATA3219 is an Allogeneic CAR T-Cell Therapy Targeting CD19+ B Cells to Potentially Address the Root Cause of Lupus Nephritis (LN)ATA3219 Is Designed to Combine the Natural Biology of Unedited T Cells and the Benefits of an Allogeneic CAR T Approach With Preclinical Data Demonstrating Potential Efficacy in LNSecond I...

Related Keywords

California ,United States ,Ukraine ,Denver ,Colorado ,Cokey Nguyen ,Rajani Dinavahi ,Securities Exchange ,Exchange Commission ,Drug Administration ,Nasdaq ,Corporate Communications Investor Relations ,Atra Biotherapeutics Inc ,Linkedin ,Atara Biotherapeutics Inc ,Potentially Address ,Root Cause ,Lupus Nephritis ,Natural Biology ,Uneditedt Cells ,Following Non Hodgkin ,Investigational New Drug ,Chief Medical Officer ,Chief Scientific ,Technical Officer ,Securities Act ,Securities Exchange Act ,Middle East ,Southern California ,Financial Condition ,Refractory Systemic Autoimmune Diseases ,Monocentric Experience ,First Fifteen ,Media Relations ,Corporate Communications ,Investor Relations ,